BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) Files An 8-K Other Events
Item 8.01. Other Events.
On March 18, 2019, the Company issued a press release that announced, with great sadness, that Thomas L. Wegman, President of the Company, passed away on March 13, 2019. Mr. Wegman served as an officer of BioSpecifics for over 20 years and as a member of the Company’s Board of Directors since 1994. The Company will continue to be actively managed by its current employees and the Company’s Board of Directors. Succession planning is underway and new management positions will be announced.
The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d)
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated March 18, 2019. |
BIOSPECIFICS TECHNOLOGIES CORP Exhibit
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Biospecifics Technologies Corp.: Exhibit 99.1 – Filed by newsfilecorp.com BioSpecifics Technologies Corp. Announces Passing of President Thomas L. WegmanLYNBROOK,…
To view the full exhibit click here
About BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC)
BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. Its injectable collagenases are marketed for indications, such as Dupuytren’s contracture and Peyronie’s disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren’s contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.
